交銀:上調舜宇光學(2382.HK)評級至買入 目標價升至130港元
交銀國際發表研究報告表示,舜宇光學(2382.HK)去年業績超出該行及市場預期,主要是由於手機鏡頭及模組的平均售價好於預期,令收入和毛利率較預期高。該行將其評級由“中性”上調至“買入”,基於2020/21年每股盈利平均值的23倍,將目標價由115港元上調至130港元。
報告指,公司今年資本支出將專注於產能升級和未來增長計劃,而不是繼2019年後再次提升短期產能。出貨量方面,公司指引今年手機鏡頭、攝像頭模組及車載鏡頭分別按年增長10%、15%及20%。
交銀表示,雖然近期需求受到打擊,但公司的長期前景不變,舜宇股價隨大市下跌了30%,將可視為長線買入良機。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.